The human T-cell leukemia virus type 1 (HTLV-1) was the first retrovirus discovered to be causative of a human cancer, adult T-cell leukemia. The transforming entity of HTLV-1 has been attributed to the virally-encoded oncoprotein, Tax. Unlike the v-onc proteins encoded by other oncogenic animal retroviruses that transform cells, Tax does not originate from a c-onc counterpart. In this article, we review progress in our understanding of HTLV-1 infectivity, cellular transformation, anti-sense transcription and therapy, 30 years after the original discovery of this virus.
Introduction
Human T-cell leukemia virus type 1 (HTLV-1) was the first human retrovirus identified 30 years ago as a causative agent of adult T-cell leukemia (ATL; see review Takatsuki, 2005) . It was isolated in 1980 in the United States (Poiesz et al., 1980) and then in Japan (Yoshida et al., 1982) . The events of virus discovery in the United States and Japan (Gallo, 2005; Yoshida, 2005) have been reviewed well elsewhere. Currently, HTLV-1 infects B20 million individuals worldwide (Proietti et al., 2005) . Besides ATL, HTLV-1 infection can also cause a chronic inflammatory disease termed HTLV-1-associated myelopathy (HAM)/tropical spastic paraparesis (TSP) (Gessain et al., 1985; Osame and Igata, 1989) . The role of HTLV-1 in HAM/TSP will not be discussed here. Below we summarize and update insights relevant to human leukemogenesis learned over the past 30 years from HTLV-1.
HTLV-1 infectivity and spread in vivo
Like other animal retroviruses, the HTLV-1 proviral genome has structural genes, gag, pol and env, bracketed by long terminal repeat (LTR) sequences (Figure 1 ). The 5 0 LTR serves as the viral promoter for transcription. The Pol open reading frame encodes reverse transcription, protease and integrase functions. Gag provides the virion core proteins, and Env is used for viral infectivity. The HTLV-1 genome has a pX region located between env and the 3 0 -LTR. pX contains sequences for regulatory viral factors, Tax, Rex, p12, p13, p30 and p21. More recently, the minus strand of pX has been found to encode an antisense transcript, HTLV-1 basic leucine zipper factor (Hbz) (Gaudray et al., 2002; Cavanagh et al., 2006; Satou et al., 2006; Matsuoka and Green, 2009 ) discussed in further detail below.
HTLV-1 can infect a variety of cell types, including T cells, B cells, fibroblasts and macrophages (Koyanagi et al., 1993; Jones et al., 2008) indicating that the receptor is commonly expressed on these cells. Recent studies show that glucose transporter 1, heparan sulfate proteoglycans and neuropilin-1 are the three proteins important for the entry of HTLV-1 (Manel et al., 2003; Jones et al., 2005; Lambert et al., 2009) . One way to view the entry events is to consider that the virus could first contact heparan sulfate proteoglycan and then form complexes with neuropilin-1 followed by Glut1 association on the cell surface before final membrane fusion and entry into the cell (Figure 2) . Currently, how all these factors cooperate with each other and with a newly described extracellular matrix-mediated transmission (Pais-Correia et al., 2010) or via dendritic cell-assisted infection (Jones et al., 2008) requires further delineation. Moreover, it should be noted that despite the ubiquitous distribution of these factors, the HTLV-1 provirus is detected mainly in CD4 þ T cells and to a lesser extent in CD8 þ T cells (Yasunaga et al., 2001) . This asymmetry in detection may be because HTLV-1 infection recruits CD4 þ T cells into proliferative cell cycling while it seems to simply delay cell death in CD8 þ T cells (Sibon et al., 2006) . Thus, the differential outcome of the virus on CD4 þ and CD8 þ cell proliferation may be more important than receptorbinding and cellular entry differences in dictating the apparent specificity for CD4 þ cells (Zane et al., 2010) . However, there is also evidence that cellular receptors have an important role in determining the cellular tropism of HTLV-1 (Jones et al., 2006) .
Unlike the human immunodeficiency virus-1, HTLV-1 is primarily transmitted through cell-to-cell contact, not by cell-free virions (Igakura et al., 2003) . HTLV-1 infected cells form virological synapses with uninfected cells. Tax and the intercellular adhesion molecule-1 have important roles in the formation of the virological synapse (Nejmeddine et al., 2009) . Enveloped viral particles can transfer through this synapse, thus propagating infection (Majorovits et al., 2008) . Recently, it has been reported that HTLV-1 cell-to-cell transmission is 10 000 times more efficient than cell-free infection, whereas for human immunodeficiency virus-1 cell-cell coculturing enhances infection only twofold (Mazurov et al., 2010) . The importance of in vivo cell-tocell spread is tempered by findings that the administration of reverse transcriptase inhibitors to HTLV-1 infected patients with HAM/TSP does not markedly influence the provirus load (Taylor et al., 2006) , and that reverse transcriptase inhibitor treatment immediately after infection by HTLV-1 in vivo does not change subsequent proviral load. Thus, viral replication itself appears not to be critical for the maintenance of persistent infection; rather, the proliferation of HTLV-1 infected cells seems to determine the viral burden during the carrier state. In this regard, the virus' strategy to increase the number of infected cells by promoting cellular proliferation is purposeful. Indeed, a long standing observation is that HTLV-1 induces clonal proliferation of infected cells in vivo (Etoh et al., 1997; Cavrois et al., 1998; Zane et al., 2010) .
Host immune and inflammatory responses to HTLV-1
A persistent virus infection establishes an equilibrium between viral virulence and the host immunity (Virgin et al., 2009) . Viruses that maintain chronic infection should evade the host's attempt at sterilizing immunity. A balance is reached when the extent of inflammation and viral replication avoid the creation of excessive tissue damage. Accordingly, viruses that cause chronic infection have evolved strategies to moderate the host immune system and temper viral replication.
For HTLV-1, it has been reported that an accessory viral protein, P12, physically interacts with the human major histocompatibility complex class I heavy chains, leading to the latter's degradation (Johnson et al., 2001) ; this process then facilitates viral escape from the host immune system. In the same vein, moderate HTLV-1 replication appears to arise from in vivo suppression of tax expression (Hanon et al., 2000) . CD8 þ cell-mediated cytotoxic T-lymphocytes (CTLs) are in part responsible for this phenomenon because their depletion enhances Tax expression in vivo (Hanon et al., 2000) . These CD8-celldependent CTLs appear to target directly the Tax protein because when histone deacetylase inhibitor, valproate, is used to activate tax transcription, the HTLV-1 proviral load in HAM/TSP individuals becomes reduced (Lezin et al., 2007) . Thus, the host's CTL-response targets Taxexpressing cells thereby reducing the number of infected cells in vivo. On the other hand, the role played by antibodies to HTLV-1 remains largely unknown.
During ATL progression, opportunistic infections can be frequent complications (Matsuoka and Jeang, 2007) . 
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Cell-mediated immunity becomes progressively impaired in ATL patients as indicated by lowered reactivity to the purified protein derivative of Mycobacterium tuberculosis recall antigen (Welles et al., 1994) . In this setting, Strongyloides stercoralis infection has been reported to become widely disseminated (Gotuzzo et al., 1999) . Alternatively, Strongyloides infection in HTLV-1 carriers (Nakada et al., 1987) who have yet to develop frank immunodeficiency has been correlated with increased propensity for ATL. This finding may relate to observations that coinfection of HCV in HTLV-1 carriers increases the risk of liver cancers (Boschi-Pinto et al., 2000) suggesting that chronic inflammation (Rauch et al., 2009) elicited by multiple agents and T-cell activation (Swaims et al., 2010) as well as Tax-induced T-cell proliferation (Maruyama et al., 1987) contribute to the in vivo promotion of ATL. It has been reported that ATL cells express FoxP3 in approximately two-third of the ATL cases (Karube et al., 2004) . As foxp3 is a master gene that controls regulatory functions of regulatory T cells, this finding indicates that ATL could be a neoplastic disease of regulatory T cells. Such immunosuppressive phenotypes of ATL cells may account for the immunodeficiency observed in ATL patients. Regulatory T cells express chemokine receptor, C-C chemokine receptor 4 (CCR4), on the surface, and ligands for CCD4 and CCL22; these cells are increased in HTLV-1 infected individuals (Toulza et al., 2010) . Enhanced production of CCL22 might contribute mechanistically to increased regulatory T cells in HTLV-1 infected individuals (Toulza et al., 2008) .
Multifaceted processes in the transformation of virus infected cells
A subset (6.6% for males and 2.1% for females in Japan) of HTLV-1 infected individuals will develop adult T-cell leukemia (ATL) after an extended period of time (Matsuoka and Jeang, 2007) . HTLV-1 encodes a Tax oncoprotein (Figure 1 ; Grassmann et al., 2005; Higuchi and Fujii, 2009) , which confers survival and proliferative properties to infected cells. Tax is posttranslationally modified by phosphorylation, ubiquitination and acetylation (Chiari et al., 2004; Peloponese et al., 2004; Marriott and Semmes, 2005; Durkin et al., 2006; Jeong et al., 2009; Lodewick et al., 2009; Peloponese et al., 2009 ). These posttranslational modifications have been experimentally shown to be important for Tax function. Expression of Tax-alone has been postulated to be sufficient for the immortalization, but not the transformation of human T cells (Rosin et al., 1998; Robek and Ratner, 1999 ). Tax's in vivo transforming capacity has been investigated extensively using transgenic mouse models; all results suggest that the sole expression of Tax can capably drive in vivo tumor formation (Grossman et al., 1995; Hasegawa et al., 2006; Ohsugi et al., 2007) . However, because mice have a more relaxed transformation threshold than humans (Haller et al., 2006) , whether Tax expression alone is sufficient for human ATL leukemogenesis remains to be clarified. The finding that mouse primary cells are substantially more easily transformed than human primary cells has been well characterized by others (Hahn et al., 1999) . Nevertheless, several biological properties of Tax as outlined below are compatible with its transforming potential in human cells.
Activation of cellular survival and proliferative pathways Virus infected cells need to evade apoptosis and commence proliferation as a prelude to immortalization and transformation (Figure 3 ). In the setting of HTLV-1 infection, the nuclear factor-kappaB (NF-kB) and Akt pathways are two major cellular prosurvival routes activated by Tax. NF-kB is constitutively active in HTLV-1-infected cells . There are at least three ways that Tax can modulate cellular NF-kB activity. First, Tax can bind the IKKg protein and activate the IKKa/IKKb/IKKg complex (Chu et al., 1999; Harhaj and Sun, 1999; Jin et al., 1999) leading to NF-kB (p50/p65) migration into the nucleus, where it activates the transcription of NF-kB-responsive genes (Iha et al., 2003) . Second, Tax can stimulate a non-canonical NF-kB pathway through the IKKadependent processing of the NF-kB p100 precursor protein to its active p52 form (Xiao et al., 2001 ) (Shoji et al., 2009) . Third, Tax can inactivate the cellular Tax1BP1 adaptor protein, which promotes deubiquitination and represses TRAF6-NF-kB signaling. By attenuating Tax1BP1 function, Tax enhances signaling through the TRAF6-NF-kB pathway (Shembade et al., 2007; Iha et al., 2008) .
Akt is a serine/threonine kinase regulated by phosphatidylinositol 3-kinase through site-specific phosphorylation on Ser473 (Song et al., 2005) . Tax binds phosphatidylinositol 3-kinase and promotes Akt phosphorylation and its activation . Activated Akt can then enhance cellular survival in part through the induction of activator protein 1 responsive genes (Jeong et al., 2008) . This route is an additionally significant cellular prosurvival/proproliferative path stimulated by Tax.
In addition to Akt and NF-kB, Tax has been shown to increase cyclin D2 expression through direct activation of its promoter (Santiago et al., 1999) , to activate CDKs, such as CDK4, through direct protein binding (Haller et al., 2002; Fraedrich et al., 2005) , and to repress CKIs, such as INK4A, INK4B (Suzuki et al., 1996; Low et al., 1997) , INK4C (Akagi et al., 1996) , INK4D (Suzuki et al., 1999; Riou et al., 2000) and KIP1 (Iwanaga et al., 2001) . These interactions result in accelerated cell cycling of HTLV-1 infected cells (Neuveut et al., 1998) (Boxus et al., 2008) promoting in vivo clonal expansion (Zane et al., 2010) .
Neutralization of cellular checkpoints
Aberrant cellular proliferation is physiologically reined in by a multitude of cellular checkpoint functions. A key cellular checkpoint is enforced by the p53 protein. Accordingly, in order to achieve successful transformation, B50% of human cancers have function-disabling mutations in p53. Many cancer causing viruses have evolved multifaceted mechanisms to inactivate p53 (Soria et al., 2010) . Curiously, mutations which inactivate p53 are infrequent in ATL cells (Yasunaga and Matsuoka, 2007) . Nevertheless, in the absence of genetic mutation of p53, the p53 checkpoint is functionally inactivated in HTLV-1 infected cells by the Tax protein (Reid et al., 1993; Tabakin-Fix et al., 2006) . How p53 is mechanistically inactivated in ATL remains incompletely clarified. Several redundant mechanisms (Ariumi et al., 2000; Pise-Masison et al., 2000; Miyazato et al., 2005) appear to be used by Tax. It is also currently unanswered whether cellular phosphatases such as Wip1 (Lindqvist et al., 2009) , which counteract p53 activity are co-opted by Tax.
ATL cells are highly aneuploid . A spindle assembly checkpoint (SAC) normally operates in mitosis to preserve euploidy by monitoring the fidelity of mitotic chromosomal segregation (Chi and Jeang, 2007) . SAC proteins, such as MAD1, MAD2, MAD3/BUBR1, BUB1, BUB3 and MSP1 function at kinetochores (Chi and Jeang, 2007) . It has been noted that SV40 (Hein et al., 2009 ), Epstein-Barr virus (Pan et al., 2009 ) and human papillomavirus (Patel and McCance, 2010) infected cells have attenuated SAC function. Similarly, the loss of SAC function has also been verified in several ATL cells (Kasai et al., 2002) . Mechanistically, the inactivation of SAC in ATL occurs through Tax binding to the checkpoint protein MAD1 (Jin et al., 1998) whose loss of function leads to tumorigenesis (Iwanaga et al., 2007) (Figure 3 ). Tax binding to and inactivation of the anaphase-promoting complex/cyclosome, which functions downstream of the SAC (Liu et al., 2005) , and Tax promotion of multipolar mitosis (Peloponese et al., 2005) have also been postulated to contribute to the prevalent aneuploidy observed in ATLs.
DNA damage and attenuation of repair DNA damage induced by Tax (Majone et al., 1993; Majone and Jeang, 2000) (Majone et al., 2005) and other oncoproteins (Felsher and Bishop, 1999) (Ramadan et al., 2008) (Vafa et al., 2002 ) is well-documented. In principle, damaged DNA can be created in two ways. First, the oncoprotein can attenuate damage sensing checkpoint and repair proteins. Second, the oncoprotein can directly elicit DNA lesions. It has been shown that Tax represses the cell's DNA polymerase b enzyme, which is used for base excision repair (Jeang et al., 1990; Philpott and Buehring, 1999) . Similarly, Tax also suppresses nucleotide excision repair (Kao and Marriott, 1999; Lemoine et al., 2000) and the expression of human DNA mismatch repair genes (Morimoto et al., 2005) . Furthermore, although it was suggested originally that Tax weakens the action of ATR/CHK1 DNAdamage signaling (Park et al., 2004) , many subsequent studies have found that Tax more potently inactivates the ATM/CHK2 axis ( Figure 3 ) and downstream repair factors (Park et al., 2006; Gupta et al., 2007; Durkin et al., 2008; Ramadan et al., 2008; Chandhasin et al., 2008; Belgnaoui et al., 2010) . Collectively then, through Tax's inactivation of DNA-damage sensing and repair proteins, ambient DNA lesions that might have been repaired in cells are permitted to accumulate.
In addition to allowing the persistence of genetic lesions, Tax was recently found to also induce reactive oxygen species, which can directly create damaged DNA (Kinjo et al., 2010) . Tax induction of reactive oxygen Figure 3 Putative cellular events that are important for ATL development. HTLV-1 infects either CD4 þ cells or a hematopoietic progenitor cell. Infected cells activate survival pathways NF-kB and Akt to evade apoptosis and senescence. Inactivation of p53 and activation of CDKs accelerate cellular proliferation. Tax attenuation of the SAC protein, Mad1, Tax reduction of DNAdamage repair, and Tax activation of reactive oxygen species (ROS) lead to aneuploidy and clastogenic damage. Late in ATL development when Tax expression is extinguished HBZ, micro-RNA changes and TP53INP1 inactivation may be important to achieve a fully transformed phenotype.
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species is consistent with similar reactive oxygen speciesinduction by other viral transforming proteins, such as Ras (Lee et al., 1999) , c-Myc (Vafa et al., 2002) and Epstein-Barr virus EBNA-1 protein (Gruhne et al., 2009) . Collectively, the creation of new DNA damage and the prevention of ambient repair lead to a picture of significant clastogenic damage as reported for Taxexpressing cells (Majone and Jeang, 2000) .
Changes in microRNAs (miRNAs) with oncogenic potentials Various cancers have different miRNA signatures (Lu et al., 2005; Bouzar and Willems, 2008; Croce, 2009) . Three recent reports have described changes in miRNA expression in ATL cells (Pichler et al., 2008; Yeung et al., 2008; Bellon et al., 2009) . As the experimental settings were different, there was considerable discordance in the individual miRNA changes that were reported (Ruggero et al., 2010) . However, a salient consensus (that is, TP53INP1) did emerge from the studies. Thus, Yeung et al., reported that the tumor suppressor protein TP53INP1 in HTLV-1-infected/ transformed cells was repressed by miR-93 and miR130b (Yeung et al., 2008) , whereas a second report found that TP53INP1 was targeted in HTLV-1-infected/ transformed cells by miR-21, -24, -146a and -155 (Pichler et al., 2008) . A third report described ATL cells with increased expression of miR-155 (Bellon et al., 2009) . Interestingly, miR-155 has been reported to be a silencer of TP53INP1 (Gironella et al., 2007) , reinforcing the notion that TP53INP1 may be a critical factor in ATL transformation. That oncogenic miRNAs contribute to ATL is further strengthened by a recent finding that small molecular inhibitors of miRNA functions can selectively reverse the dysregulated proliferation of several HTLV-1-transformed cells (Watashi et al., 2010) , and by the finding that Tax can induce the expression of some cellular miRNAs (Yeung et al., 2008) . Taken together, the perturbation of oncogenic miRNAs in ATL may represent an additional multifaceted factor that needs to be considered for in vivo leukemogenesis.
HTLV-1 antisense transcript HBZ and viral pathogenesis
The 3 0 portion of the HTLV-1 genome has been shown to direct sense (plus) and antisense (minus) transcripts that encode different proteins (Figure 1) (Cavanagh et al., 2006; Satou et al., 2006) . The plus strand of this region contains transcripts directed from the 5 0 LTR, whereas the 3 0 LTR directs a novel antisense transcript termed the HTLV-1 bZIP factor, Hbz (Figure 1) . The promoter for the Hbz gene is derived from U5 sequence of the 3 0 LTR. Mutational analyses of this promoter region show that three Sp1 sites are critical for HBZ transcription (Yoshida et al., 2008) . As the expression of Sp1 is relatively constant in most cells, Hbz gene expression is well correlated with the amount of integrated provirus in HTLV-1-infected individuals (Saito et al., 2009 ).
Although tax transcripts are detected in only B40% of transformed ATL cells, it was recently demonstrated that Hbz RNA is ubiquitously expressed in all ATL cells, and possesses cell proliferative function (Satou et al., 2006) . The HBZ protein has been ascribed to interact with CREB, CREB-2, CREM-Ia, ATF-1 (Lemasson et al., 2007) , c-Jun (Basbous et al., 2003; Matsumoto et al., 2005) , JunB and JunD (Thebault et al., 2004) through its bZIP domain, and was originally reported to suppress Tax-mediated viral transcription (Gaudray et al., 2002) . Furthermore, HBZ selectively inhibits the classical NF-kB pathway by inhibiting DNA binding of p65 and promoting the degradation of p65 (Zhao et al., 2009) . Tax can activate both classical and alternate NF-kB pathways. The two pathways differentially control genes with anti-apoptotic functions in lymphoma cell lines (Bernal-Mizrachi et al., 2006) . Predominant activation of the alternate pathway by Tax and HBZ might be implicated in the proliferation of ATL cells.
A further study suggested that the Hbz RNA, besides its protein form, is also important for the proliferation of HTLV-1-infected cells. Moreover, it has been shown that an HTLV-1 molecular clone with a mutation in the leucine zipper domain of HBZ, exhibited reduced proviral load compared with wild-type virus when inoculated into rabbits (Arnold et al., 2008) and that HBZ can increase the activity of the human telomerase reverse transcriptase gene (Kuhlmann et al., 2007) . Collectively, the extant data support that HBZ protein and Hbz RNA have roles in promoting viral replication and cellular proliferation. One potential way to interpret the interplay between Tax and HBZ is that the former is needed to initiate transformation while the latter is required to maintain the transformed phenotype late in ATL when Tax expression is extinguished. Whether HBZ also has roles in HTLV-1-associated HAM/TSP disease remains to be clarified (Saito et al., 2009) .
Therapeutic approaches for ATL
In many ways, ATL is a poorly treatable disease. Patients with acute or lymphoma-type ATL are usually addressed with combination chemotherapy (Figure 4) . The representative protocol for ATL patients in Japan is vincristine, cyclophosphamide, doxorubicin and prednisone (VCAP), doxorubicin, ranimustine, and prednisone (AMP), and vindesine, etoposide, carboplatin, and prednisone (VECP) (VCAP-AMP-VECP). This protocol was found to be superior to biweekly CHOP therapy (Tsukasaki et al., 2007) . It has been found that the complete response rate was higher with VCAP-AMP-VECP than biweekly CHOP (40 vs 25%). Indeed, the overall survival at 3 years was 24% in the VCAP-AMP-VECP arm and 13% in the CHOP arm. The major obstacles in therapy are the drug resistance of ATL cells to chemotherapeutic agents and the profoundly weakened and immunodeficient state of ATL patients. The cause of ATL immunodeficiency may be from the immunosuppressive function of ATL cells, as they appear to arise from regulatory T cells (Karube et al., 2004) and can produce immunosuppressive cytokines (Mori et al., 1996) . As noted above, ATL immunodeficiency leads to complications from various opportunistic fungal, viral, protozoal and bacterial infections, which can worsen the prognosis.
Allogeneic stem cell transplantation has been shown to be effective in ATL patients (Utsunomiya et al., 2001) . Patients treated with allogeneic stem cell transplantation with reduced-intensity conditioning had overall survival at 3 years of 36% (Tanosaki et al., 2008) . These studies showed that 30-40% of ATL patients, who achieve remission and have suitable donors, became long-term survivors with either conventional allogeneic stem cell transplantation (SCT) or reduced-intensity conditioning (Okamura et al., 2007) . It should be noted that provirus load remarkably decreased in many patients who received SCT. The findings suggest that cell-mediated immunity to HTLV-1 was augmented in these patients, which might account for the efficacy of this therapy.
The presence of graft-versus-host disease is a good prognostic factor for ATL patients (Okamura et al., 2007) , indicating that immune attack by donor lymphocytes is critical for the efficacy of treatment. ATL cells express Fas antigen highly are susceptible to Fasmediated signaling (Tamiya et al., 1998; Yasunaga et al., 2004) . CTLs can attack ATL cells in the host, resulting in good therapeutic responses. In allogeneic stem cell transplantation treated individuals, CTLs to Tax peptides were activated in the recipients; and provirus load became profoundly suppressed, indicating the role of anti-HTLV-1 immune responses in the efficacious outcome (Harashima et al., 2004) . Nevertheless, it remains unknown whether CTLs to Tax are required for the efficacy of stem cell transplantation therapy.
Of therapeutic implication, it has been noted that most ATL leukemic cells express CCR4 molecules on their surfaces (Yoshie et al., 2002) . As T reg cells express CCR4, this finding is consistent with one of the origins of ATL cells as T reg cells. KW-0761, a defucosylated humanized anti-CCR4 antibody, has been shown to be effective in ATL patients (Yamamoto et al., 2010) . Among 15 patients treated with KW-0761, 5 patients achieved positive objective responses: 2 complete and 3 partial responses. Potentially, the KW-0761 antibody could be beneficial when combined with rituximab treatment.
It has been reported that the mean survival time of patients with indolent subtypes, chronic and smoldering ATL was 4.1 years. This finding shows that the prognosis of indolent ATL is poorer than previously thought (Takasaki et al., 2010) . Therapy using interferon a combined with zidovudine ( Figure 4 ) has been reported to be highly effective to these indolent ATL (Bazarbachi et al., 2010) suggesting that such therapy could be beneficial for this category of patients.
Experiments using animal models have provided important information on therapeutic strategies for ATL patients. For example, monoclonal antibodies to CD25 (Phillips et al., 2000) , CD2 (Zhang et al., 2003b) , CD52 (Zhang et al., 2003a) and CCR4 (Ishii et al., 2010) have been shown to be effective to ATL cells within in vivo model. In addition, it has been reported that a proteasome inhibitor, bortezomib, suppresses tumor formation of ATL cells in vivo (Tan and Waldmann, 2002; Mitra-Kaushik et al., 2004; Satou et al., 2004) . NF-kB inhibitors also effectively induce apoptosis of ATL cells as NF-kB is highly activated in ATL cells (Dewan et al., 2003; Watanabe et al., 2005) . These findings suggest the potential efficacy of these compounds and antibodies although they remain to be verified in clinical studies.
Concluding remarks
Recent developments suggest that cancers, whether solid tumors (for example, breast and lung) or hematological malignancies (for example, leukemia), are comprised of two categories of cells: those with high-and those with limited-proliferative potential. Cells in the former category are termed cancer stem cells. Cancer stem cells share several properties with adult stem cells, particularly the abilities to self-renew and differentiate into multiple cell types. Cancer stem cells are found in a given cancer as a small sub-population; and cancer stem cells are reasoned to be the moieties, which cause disease relapse and metastasis. They, unlike the bulk of tumor cells, are postulated to be the only cells capable of giving rise to new tumors. Currently, an outstanding question in HTLV research is whether ATL originates from the transformation of a differentiated CD4 þ T cells or from virus infection and transformation of a hematopoietic precursor cell (Banerjee et al., 2008 (Banerjee et al., , 2010 . Many attempts to transform human CD4 þ T cells with Tax have failed; and it remains to be seen whether hematopoietic precursor cells or human stem cells can be transformed by Tax. Success in the latter attempts would point to factors that are expressed in undifferentiated, rather than differentiated, cells that may be critical to ATL leukemogenesis. Certainly, we expect 
Conflict of interest
The authors declare no conflict of interest.
